Mobilised peripheral blood cells - Cellect Biotechnology

Drug Profile

Mobilised peripheral blood cells - Cellect Biotechnology

Alternative Names: ApoGraft™; Mobilised peripheral blood cells - Cellect Biotechnology; Mobilised peripheral blood product - Cellect Biotechnology

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellect Biotechnology
  • Developer Cellect Biotechnology; Hadassah Medical Organization
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Graft-versus-host disease

Most Recent Events

  • 04 Jan 2018 Safety data from a phase I/II trial in Graft-versus-host disease released by Cellect Biotechnology
  • 05 Sep 2017 Mobilised peripheral blood cells receives Orphan Drug status for Graft-versus-host disease (Prevention) in USA
  • 03 Apr 2017 Cellect Biotechnology receives a notice of intention to grant for a patent covering a key method of treatment the the European Patent Office
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top